Myriad Genetics' Q3 Revenues Rise 5 Percent
May 05, 2010
Myriad Genetics' Q3 Revenues Rise 5 Percent
The firm's sales were constrained by market conditions and it failed to meet analysts' expectations on both the top and bottom line.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Myriad's Q2 Revenues Increase 21 Percent; New $200M Stock Buyback Program Launched
February 6, 2013 / GenomeWeb Daily News - Myriad Genetics' Q2 Revenues Climb 8 Percent
January 28, 2011 / GenomeWeb Daily News - Myriad's Q4 Revenues Rise 9 Percent; 2010 Revenues up 11 Percent
August 11, 2010 / GenomeWeb Daily News - Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter - Myriad to Launch NGS MyRisk Hereditary Cancer Panel this Year, Replace Existing Tests by Mid-2015
May 15, 2013 / Clinical Sequencing News